Working... Menu
Trial record 2 of 3 for:    PF-04494700

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00141661
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : August 20, 2009
Trans Tech Pharmaceuticals
Information provided by:

Brief Summary:
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: PF-04494700 - Low Dose Arm Drug: PF-04494700 - High Dose Arm Drug: Placebo Comparator Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700
Study Start Date : October 2005
Actual Primary Completion Date : June 2006
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Low Dose Arm Drug: PF-04494700 - Low Dose Arm
30 mg loading dose for 6 days, followed by 10 mg daily

Experimental: High Dose Arm Drug: PF-04494700 - High Dose Arm
60 mg loading dose for 6 days, followed by 20 mg daily

Placebo Comparator: Placebo Control Drug: Placebo Comparator
Matching placebo.

Primary Outcome Measures :
  1. Safety Measures include Adverse Events [ Time Frame: Every Visit ]
  2. Laboratory Tests [ Time Frame: Every Office Visit ]
  3. 12-Lead Electrocardiogram [ Time Frame: Every Office Visit ]
  4. 24-Hour 12-Lead Serial ECGs [ Time Frame: Baseline, Study End ]

Secondary Outcome Measures :
  1. Surrogate Efficacy Markers in Plasma: A-Beta, C-Reactive Protein, IL-1, IL-6, Isoprostanes, TNF-alpha, TNF-beta [ Time Frame: Baseline, Visit 5, Study End ]
  2. Cognitive Function Tests: ADAS-Cog, CDR-Sum of Boxes, MMSE, ADCS-ADL [ Time Frame: Screening Visit, Baseline, Study End ]
  3. Pharmacokinetic Profile [ Time Frame: Baseline and Every Office Visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probably Alzheimer's disease for at least 1 year.
  • Mini Mental State Exam (MMSE) score between 12-26 at screening.
  • Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months.

Exclusion Criteria:

  • Current evidence of a neurological or psychiatric illness that could contribute to dementia.
  • Living alone.
  • Poorly controlled high blood pressure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00141661

Layout table for location information
United States, Arizona
Pfizer Investigational Site
Sun City, Arizona, United States, 85351
United States, California
Pfizer Investigational Site
Fresno, California, United States, 93720
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Francisco, California, United States, 94118
United States, Florida
Pfizer Investigational Site
Fort Lauderdale, Florida, United States, 33321
Pfizer Investigational Site
Fort Myers, Florida, United States, 33912
Pfizer Investigational Site
Hallandale Beach, Florida, United States, 33009
Pfizer Investigational Site
Jacksonville, Florida, United States, 32216
Pfizer Investigational Site
Largo, Florida, United States, 33773
Pfizer Investigational Site
Orlando, Florida, United States, 32806
Pfizer Investigational Site
West palm Beach, Florida, United States, 33407
United States, Tennessee
Pfizer Investigational Site
Memphis, Tennessee, United States, 38119
Sponsors and Collaborators
Trans Tech Pharmaceuticals
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00141661     History of Changes
Other Study ID Numbers: B0341008
First Posted: September 1, 2005    Key Record Dates
Last Update Posted: August 20, 2009
Last Verified: August 2009

Keywords provided by Pfizer:
Interventional, Alzheimer, Safety and Tolerability

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders